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ABSTRACT
This open-label, multicenter, phase 1B/2 trial assessed AUY922 plus trastuzumab 
in patients with locally advanced or metastatic HER2-positive breast cancer previously 
treated with chemotherapy and anti-HER2 therapy. This study was composed of a 
dose-escalation part with AUY922 administered weekly at escalating doses with 
trastuzumab 2 mg/kg/week (phase 1B), followed by a phase 2 part using the same 
regimen at recommended phase 2 dose (RP2D). The primary objectives were to 
determine the maximum tolerated dose (MTD) and/or RP2D (phase 1B), and to 
evaluate preliminary antitumor activity (phase 2) of AUY922 plus trastuzumab at 
MTD/RP2D. Forty-five patients were treated with AUY922 plus trastuzumab (4 in 
phase 1B with AUY922 at 55 mg/m2 and 41 in phase 1B/2 with AUY922 at 70 mg/m2 
[7 in phase 1B and 34 in phase 2]). One patient in phase 1B (70 mg/m2) experienced 
a dose-limiting toxicity (grade 3 diarrhea); the RP2D was weekly AUY922 70 mg/m2 
plus trastuzumab. Of the 41 patients in the 70 mg/m2 cohort, the overall response rate 
(complete or partial responses) was 22.0% and 48.8% patients had stable disease. 
Study treatment-related adverse events occurred in 97.8% of patients; of these, 
31.1% were grade 3 or 4. Forty-one patients (91.1%) reported ocular events (82.3% 
had grade 1 or 2 events). Two patients (4.4%) had ocular events leading to the 
permanent discontinuation of study treatment. AUY922 at 70 mg/m2 plus trastuzumab 
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standard therapy is well tolerated and active in patients with HER2-positive metastatic 
breast cancer who progressed on trastuzumab-based therapy.
INTRODUCTION
HER2 is overexpressed or amplified in 
approximately 15% to 20% of all cases of breast cancer 
[1]. Trastuzumab, a monoclonal anti-HER2 antibody, was 
the first biologically targeted therapy approved for the 
treatment of patients with advanced or metastatic HER2-
positive breast cancer [2]. As a single agent, the overall 
response rates (ORR) of trastuzumab range between 12% 
and 26% [3–5]; ORR in patients with HER2 overexpressed 
tumors based at the 3+ level by immunohistochemistry 
was 35% [5]. Trastuzumab monotherapy improved 
disease-free survival in patients with HER2-positive breast 
cancer in the adjuvant setting (eg, HERceptin Adjuvant 
[HERA] trial) [6].
Trastuzumab has been used as the first-line treatment 
in combination with chemotherapy such as docetaxel or 
paclitaxel in locally advanced or metastatic HER2-positive 
breast cancer, with response rates ranging between 50% 
and 80% [2, 7] and as the second-line or later treatment in 
combination with different cytotoxic agents [ORR, 20%-
68%] [8–16]. The majority of patients with metastatic 
breast cancer who initially responded to trastuzumab 
developed resistance within 1 year of treatment initiation 
[17].
Lapatinib (a dual inhibitor of epidermal growth 
factor receptor [EGFR] tyrosine kinase 1 and 2 [HER2]) in 
combination with capecitabine has been shown to prolong 
progression-free survival (PFS), and this combination is 
indicated for the treatment of patients with advanced or 
metastatic HER2-positive breast cancer who have received 
prior therapy including an anthracycline, a taxane, and 
trastuzumab [18].
Pertuzumab (a HER2-targeting antibody) when 
combined with trastuzumab and docetaxel as a first-line 
treatment prolonged overall survival (OS) in patients 
with HER2-positive metastatic breast cancer [19]. 
Trastuzumab–maytansine conjugate (TDM-1, a HER2 
antibody-drug conjugate) significantly improves PFS in 
previously treated patients with metastatic HER2-positive 
breast cancer [20, 21]. Pertuzumab and TDM-1 have been 
approved as first-line and second-line treatments for use 
in metastatic breast cancer on June 08, 2012 and February 
22, 2013, respectively.
HSP, a family of the molecular chaperones, are a 
group of proteins that play essential role in the folding 
of a large number of cellular proteins [22, 23]. HSP90 
interacts with a variety of proteins that play important 
roles in breast cancer including receptor tyrosine kinases 
such as EGFR and HER2 as well as RAF and AKT [24].
The first-generation compounds of HSP90 
inhibitors were geldanamycin derivatives, which have 
a few limitations including difficult formulation and 
hepatotoxicity [25–27]. The new, second-generation, 
synthetic HSP90 inhibitors such as AUY922 have 
greater potency and reduced hepatotoxicity. AUY922 is 
an isoxazole-based, nongeldanamycin compound, which 
competitively inhibits the ATPase activity of HSP90, 
resulting in degradation of client proteins, including HER2 
[28]. AUY922 has shown activity in preclinical breast 
cancer model, and significant synergy was observed when 
it was combined with trastuzumab in the HER-2 positive 
BT-474 breast cancer xenograft model [28]. A first-in-
human phase 1 study of AUY922 in advanced solid 
tumors showed that patients tolerated weekly infusions 
of AUY922, and dose-limiting toxicities (DLTs) occurred 
in 8 patients (7.9%) (22-70 mg/m2), which included 
diarrhea, asthenia/fatigue, anorexia, atrial flutter, and 
visual symptoms. The recommended phase 2 dose (RP2D) 
of AUY922 was declared as 70 mg/m2 once weekly [29].
Clinical data of the HSP90 inhibitor tanespimycin 
in combination with trastuzumab have shown promising 
activity in patients with HER2-positive locally advanced 
or metastatic breast cancer progressing on trastuzumab 
[30]. Ganetespib, another second-generation HSP90 
inhibitor has shown promising clinical activity (clinical 
benefit rate of 60%) in combination with paclitaxel and 
trastuzumab (clinical benefit rate was 60%) in heavily 
pretreated patients with HER2-positive metastatic BC 
[31]. This open-label, multicenter, phase 1B/2 trial 
evaluated the efficacy, safety, tolerability, biologic activity, 
and pharmacokinetic profile of AUY922 in combination 
with trastuzumab in patients with locally advanced or 
metastatic HER2-positive breast cancer previously treated 
with chemotherapy and anti-HER2 therapy.
RESULTS
Baseline characteristics and patient disposition
A total of 45 patients with HER2-positive advanced 
or metastatic breast cancer (median age, 51.0 years [range, 
29.0-71.0]) were treated with AUY922 plus trastuzumab. 
Of these 45 patients, 88.9% of patients had invasive ductal 
carcinoma, 4.4% of patients had lobular carcinoma, and 
6.7% of patients had carcinoma of other histology; 55.6% 
of patients were estrogen receptor (ER)-positive and 
42.2% of patients were ER-negative; 40.0% of patients 
were progesterone receptor (PR)-positive, and 57.8% of 
patients were PR-negative; 1 patient (2.2%) had missing 
data for both ER and PR status; 11.1%, 26.7%, and 62.2% 
of patients had received 1, 2, and ≥ 3 regimens at last 
treatment, respectively (Table 1). The trial recruited the 
first patient in September 2010, and the last patient’s 
recruitment was completed on May 2012. During this 
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Table 1: Patient demographics and disease characteristics
Characteristic, n (%) 55 mg/m
2
n = 4
70 mg/m2
n = 41
All patients
N = 45
Median age (range), years 53.5 (43.0, 64.0) 51.0 (29.0, 71.0) 51.0 (29.0, 71.0)
Age category, years    
 < 65 4 (100) 36 (87.8) 40 (88.9)
 ≥ 65 0 5 (12.2) 5 (11.1)
Race    
 Caucasian 2 (50.0) 34 (82.9) 36 (80.0)
 Black 0 1 (2.4) 1 (2.2)
 Asian 2 (50.0) 6 (14.6) 8 (17.8)
Histology    
 Invasive ductal carcinoma 3 (75.0) 37 (90.2) 40 (88.9)
  Invasive lobular 
carcinoma
0 2 (4.9) 2 (4.4)
 Other 1 (25.0) 2 (4.9) 3 (6.7)
Estrogen receptor-negative 4 (100) 15 (36.6) 19 (42.2)
Estrogen receptor-positive 0 25 (61.0) 25 (55.6)
Missing 0 1 (2.4) 1 (2.2)
Progesterone receptor-
negative
4 (100) 22 (53.7) 26 (57.8)
Progesterone receptor-
positive 0 18 (43.9) 18 (40.0)
Missing 0 1 (2.4) 1 (2.2)
Stage at diagnosis    
 I to IIb 4 (100) 20 (48.8) 24 (53.3)
 III to IIIb 0 14 (34.1) 14 (31.1)
 IV 0 5 (12.2) 5 (11.1)
 Missing 0 2 (4.9) 2 (4.4)
Metastatic sites    
 Brain 0 1 (2.4) 1 (2.2)
 Pleura 0 2 (4.9) 2 (4.4)
 Lung 2 (50.0) 22 (53.7) 24 (53.3)
 Liver 0 23 (56.1) 23 (51.1)
 Pancreas 0 1 (2.4) 1 (2.2)
 Peritoneum 0 1 (2.4) 1 (2.2)
 Breast 1 (25.0) 4 (9.8) 5 (11.1)
 Uterus 0 1 (2.4) 1 (2.2)
 Kidney 0 2 (4.9) 2 (4.4)
 Skin 1 (25.0) 2 (4.9) 3 (6.7)
 Bone 0 25 (61.0) 25 (55.6)
Oncotarget37683www.impactjournals.com/oncotarget
time, pertuzumab and TDM-1 were not approved as 
anti-HER2 treatments (see Introduction for the dates of 
approval). However, patients who received either of these 
agents were eligible for the trial. In total, 3 (6.7%) and 8 
patients (17.8%) received prior TDM-1 and pertuzumab, 
respectively. A total of 12 patients (26.7%) had received 
prior lapatinib treatment.
Four patients were treated in phase 1B with 
AUY922 at 55 mg/m2 plus weekly trastuzumab and 41 
patients were treated in phase 1B/2 with AUY922 at 70 
mg/m2 plus trastuzumab (7 patients in phase 1B and 34 
patients in phase 2). As of January 29, 2013, forty-three 
patients discontinued the treatment; the majority of 
patients (68.9%) discontinued the treatment due to disease 
progression (Table 2). Follow-up was completed in 42 out 
of 43 patients who had discontinued treatment.
Determination of maximum tolerated dose 
(MTD)/RP2D
In the first-in-human AUY922 monotherapy study, 
the RP2D was declared as 70 mg/m2 once weekly [29]. In 
this study, only 1 patient in the phase1B (70 mg/m2 cohort) 
experienced a DLT (grade 3 diarrhea) with trastuzumab. 
The RP2D was thus weekly AUY922 70 mg/m2 in 
combination with trastuzumab.
Efficacy
Among the 41 patients in the 70 mg/m2 cohort, 
the ORR (complete or partial responses) by investigator 
review was 22.0% (Table 3). From the Bayesian posterior 
distribution, the mean ORR was 22.0% [95% credible 
interval: 11.1%, 35.5%]. The best tumor shrinkage 
(computed tomography [CT] response) in target lesions in 
evaluable patients is shown in Figure 1. Twenty patients 
(48.8%) had stable disease. The median PFS was 3.94 
months (95% confidence interval [CI]: 3.48, 6.47) (Figure 
2). The Kaplan-Meier estimates of PFS rate at 4 and 6 
months were 47.9% (95% CI: 31.4, 62.7) and 38.7% (95% 
CI: 23.1, 54.1), respectively. The median OS was 12.65 
months (95% CI: 11.70, 17.22) (Figure 3). The Kaplan-
Meier estimate of OS rate at 8 months was 91.6% (95% 
CI: 76.0, 97.2).
Pharmacokinetics
Mean plasma concentration-time profiles for 
AUY922 and its metabolite BJP762 in combination with 
Characteristic, n (%) 55 mg/m
2
n = 4
70 mg/m2
n = 41
All patients
N = 45
 Lymph nodes 2 (50.0) 11 (26.8) 13 (28.9)
 Other 0 4 (9.8) 4 (8.9)
Number of regimens at last 
treatment
   
 1 0 5 (12.2) 5 (11.1)
 2 2 (50.0) 10 (24.4) 12 (26.7)
 ≥ 3 2 (50.0) 26 (63.4) 28 (62.2)
Therapy type at last 
medication
   
 Chemotherapy 2 (50.0) 24 (58.5) 26 (57.8)
 Hormonal therapy 0 7 (17.1) 7 (15.6)
 Targeted therapy 4 (100) 29 (70.7) 33 (73.3)
Prior antineoplastic therapy – 
monoclonal antibodies
   
 Trastuzumab 4 (100) 41 (100) 45 (100)
  Trastuzumab emtansine 
(TDM-1)
1 (25.0) 2 (4.9) 3 (6.7)
 Bevacizumab 0 2 (4.9) 2 (4.4)
 Pertuzumab 2 (50.0) 6 (14.6) 8 (17.8)
 Lapatinib 1 (25.0) 11 (26.8) 12 (26.7)
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trastuzumab on cycle 1 day 1 were both biphasic at doses 
of 55 mg/m2 and 70 mg/m2 (Figure 4A and Figure 4B, 
respectively).
The exposures to AUY922 and BJP762 in plasma 
for the 70 mg/m2 dose cohort were generally higher than 
those in the 55 mg/m2 cohort, indicating dose-dependent 
increase in exposure. AUY922 had a mean clearance 
(CL) value of 60 L/h (61.50 L/h for 55 mg/m2 cohort 
and 59.27 L/h for 70 mg/m2 cohort) and a mean volume 
of distribution (Vz) value of 3850 L (4541.60 L for 55 
mg/m2 cohort and 3160.83 L for 70 mg/m2 cohort) in 
plasma.
Safety
The median duration of treatment (AUY922 plus 
trastuzumab) exposure was 16.0 weeks (range, 1-72) in 
all patients; the median duration of treatment in the 55 mg/
m2 and 70 mg/m2 cohorts was 10.5 weeks (range, 7-24) 
and 16.0 weeks (range, 1-72), respectively.
Of the overall 45 patients treated with AUY922 
plus trastuzumab, 37.8% patients (17 of 45) had ≥ 1 dose 
reduction (50.0% [2 of 4] in the 55 mg/m2 cohort and 
36.6% [15 of 41] in the 70 mg/m2 cohort). All of the dose 
reductions were due to adverse events (AEs), except for 
2 patients in the 70 mg/m2 cohort (1 due to dosing error 
and 1 due to a laboratory test abnormality). Twenty-six 
patients had ≥ 1 dose delay (2 in the 55 mg/m2 cohort and 
24 in the 70 mg/m2 cohort). Overall, 46.7% patients (21 
of 45) had dose delays due to AEs (50.0% in the 55 mg/
m2 cohort [2 of 4] and 46.3% in the 70 mg/m2 cohort [19 
of 41]).
All patients reported ≥ 1 AE, regardless of study 
treatment relationship; the most common AEs were 
diarrhea (88.9%), fatigue (37.8%), nausea (37.8%), 
headache (31.1%), night blindness (31.1%), and visual 
impairment (31.1%). Overall, 21 patients (46.7%) 
experienced a grade 3 or 4 AE regardless of study 
treatment relationship; the most common grade 3 AEs 
were dyspnea, (3 patients, 6.7%) and accommodation 
disorder, anemia, arthralgia, diarrhea, decreased ejection 
fraction, fatigue, and nausea (in 2 patients each, 4.4%). Six 
patients in the 70 mg/m2 cohort experienced grade 4 AEs 
regardless of causality (anemia, hyperkalemia, jaundice, 
Table 2: Patient disposition
Patient disposition 55 mg/m
2
n = 4
70 mg/m2
n = 41
All patients
N = 45
Patients enrolled, n (%)    
 Treated 4 (100) 41 (100) 45 (100)
 Treatment discontinued 4 (100) 39 (95.1) 43 (95.6)
 Treatment ongoing 0 2 (4.9) 2 (4.4)
Primary reason for end of 
treatment, n (%)
   
 Adverse event(s) 1 (25.0) 7 (17.1) 8 (17.8)
 Subject withdrew consent 0 4 (9.8) 4 (8.9)
 Disease progression 3 (75.0) 28 (68.3) 31 (68.9)
Table 3: Best overall response by investigator review
Best overall response, n (%) 70 mg/m
2
n = 41
Complete response (CR) 1 (2.4)
Partial response (PR) 8 (19.5)
Stable disease 20 (48.8)
Progressive disease 11 (26.8)
Unknown 1 (2.4)
Objective response (CR or PR), n (%) 
[95% credible interval]
9 (22.0)
(11.1, 35.5)
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optic nerve disorder, pleural effusion, and breast cancer [2 
events in 1 patient]).
Study treatment-related AEs occurred in 97.8% 
patients; the most frequent AEs were diarrhea, fatigue, 
nausea, and visual impairment (Table 4). Study treatment-
related grade 3 or 4 AEs occurred in 14 patients (31.1%). 
The most common study-treatment related grade 3 or 4 
AEs were diarrhea, fatigue, accommodation disorder, and 
decreased ejection fraction (each occurring in 2 patients, 
4.4%).
Overall, 11 patients (24.4%) (all in the 70 mg/m2 
cohort) experienced serious AEs (SAEs), regardless of 
causality; none of these resulted in discontinuation of 
study treatment or death. Three patients (7.3%) in the 70 
Figure 2: Kaplan–Meier plot of progression-free survival as per investigator in the 70 mg/m2 cohort. ‘n’ represents 
number of patients with progressive disease or death whereas ‘N’ represents total number of patients treated with AUY922 70 mg/m2 plus 
trastuzumab. Patients who have not had events are censored, but are still included in the figure.
Figure 1: Best tumor shrinkage (computed tomography response) in target lesions among evaluable patients in the 70 
mg/m2 cohort. *Confirmed Response Evaluation Criteria in Solid Tumors response. ‘n’ represents number of patients with a baseline and 
at least 1 post-baseline tumor assessment in target lesions by investigator and ‘N’ represents total number of patients treated with AUY922 
70 mg/m2 plus trastuzumab.
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Figure 3: Kaplan–Meier plot of overall survival as per investigator in the 70 mg/m2 cohort. ‘n’ represents number of deaths 
whereas ‘N’ represents total number of patients treated with AUY922 70 mg/m2 plus trastuzumab. Patients who have not died are censored, 
but are still included in the figure.
Figure 4: Semi-logarithmic arithmetic mean concentration-time profiles for plasma AUY922 and BJP762 in 
combination with trastuzumab. A. AUY922 55 mg/m2 plus trastuzumab. B. AUY922 70 mg/m2 plus trastuzumab.
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mg/m2 cohort experienced study treatment-related SAEs; 
none of which resulted in permanent discontinuation.
Eight patients (1 patient in the 55 mg/m2 cohort and 
7 patients in the 70 mg/m2 cohort) (17.8%) discontinued 
the treatment due to AEs, regardless of study treatment 
relationship. Study treatment-related discontinuation 
events occurred in 7 patients, which included elevated 
alanine aminotransferase, hyperkalemia, optic nerve 
disorder, decreased appetite, accommodation disorder 
(each in 1 patient); and decreased ejection fraction (2 
patients).
A total of 18 deaths occurred > 28 days after the 
last dose and during the survival follow-up period (data 
cutoff, January 29, 2013). The cause of death was reported 
as disease progression in 16 patients; 1 patient died during 
brain surgery, and 1 due to acute respiratory insufficiency.
Overall, 41 patients (91.1%) reported ocular events 
regardless of study treatment relationship (all 4 patients 
in the 55 mg/m2 cohort and 37 patients in the 70 mg/
m2 cohort); the most frequent ocular events were night 
blindness (31.1%), visual impairment (31.1%), photopsia 
(28.9%), blurred vision (28.9%), and photophobia 
(11.1%). Most ocular events (82.3%) were grade 1 or 
2. Four patients (8.9%) (1 in the 55 mg/m2 cohort and 3 
in the 70 mg/m2 cohort) experienced grade 3 or 4 ocular 
events; all were study treatment related. Two patients 
(4.4%) had ocular events (grade 4 optic nerve disorder and 
grade 3 accommodation disorder) leading to permanent 
discontinuation of study treatment, both considered to be 
study treatment related.
One patient in the 70 mg/m2 cohort (2.4% of this 
cohort) experienced 2 cardiac events of interest (left 
bundle branch block and cardiac failure). Both were SAEs 
of grade 3 severity and were suspected to be related to 
study drug; neither led to permanent discontinuation of 
study treatment.
Table 4: Study treatment-related adverse events (all grades ≥ 10% and grades 3 or 4)
Preferred term,
n (%)
55 mg/m2
n = 4
70 mg/m2
n = 41
All patients
N = 45
All grades Grade  
3 or 4
All grades Grade  
3 or 4
All grades Grade  
3 or 4
Diarrhea 2 (50.0) 0 38 (92.7) 2 (4.9) 40 (88.9) 2 (4.4)
Fatigue 2 (50.0) 0 13 (31.7) 2 (4.9) 15 (33.3) 2 (4.4)
Nausea 1 (25.0) 0 14 (34.1) 1 (2.4) 15 (33.3) 1 (2.2)
Visual impairment 2 (50.0) 1 (25.0) 12 (29.3) 0 14 (31.1) 1 (2.2)
Night blindness 1 (25.0) 0 12 (29.3) 0 13 (28.9) 0
Photopsia 3 (75.0) 0 10 (24.4) 1 (2.4) 13 (28.9) 1 (2.2)
Vision blurred 2 (50.0) 0 11 (26.8) 0 13 (28.9) 0
Vitreous floaters 1 (25.0) 0 10 (24.4) 0 11 (24.4) 0
Accommodation 
disorder 1 (25.0) 0 9 (22.0) 2 (4.9) 10 (22.2) 2 (4.4)
Asthenia 0 0 8 (19.5) 1 (2.4) 8 (17.8) 1 (2.2)
Decreased appetite 0 0 7 (17.1) 0 7 (15.6) 0
Headache 1 (25.0) 0 6 (14.6) 0 7 (15.6) 0
Vomiting 1 (25.0) 0 6 (14.6) 1 (2.4) 7 (15.6) 1 (2.2)
Abdominal pain 0 0 6 (14.6) 0 6 (13.3) 0
Muscle spasms 0 0 6 (14.6) 0 6 (13.3) 0
Pruritus 1 (25.0) 0 5 (12.2) 0 6 (13.3) 0
Anemia 0 0 5 (12.2) 0 5 (11.1) 0
Hypokalemia 0 0 5 (12.2) 0 5 (11.1) 0
Photophobia 2 (50.0) 0 3 (7.3) 0 5 (11.1) 0
Visual acuity reduced 0 0 5 (12.2) 0 5 (11.1) 0
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DISCUSSION
This phase 1B/2 study evaluated the efficacy and 
safety of AUY922 plus trastuzumab in patients with 
advanced or metastatic HER-2 positive breast cancer 
progressing on trastuzumab. The rationale for this study 
was based on synergistic activity of AUY922 plus 
trastuzumab in the HER-2 positive BT-474 breast cancer 
xenograft model [28] and clinical experience of other 
HSP90 inhibitors in combination with trastuzumab in 
patients with advanced HER2-positive metastatic breast 
cancer progressing on trastuzumab [30].
In phase 1B, only 1 patient (70 mg/m2 cohort) 
experienced a DLT (grade 3 diarrhea) in combination with 
trastuzumab. According to the Bayesian logistic regression 
model, at a 70 mg/m2 dose of AUY922, the posterior risk 
of DLT rate being in the excessive toxicity category was 
much lower than 25%; hence, the dose of AUY922 could 
have been further escalated. However, at that time, the 
AUY922 first-in-human monotherapy study [29] had 
already declared 70 mg/m2 as the RP2D; thus, further 
escalation was prohibited. The dose of 70 mg/m2 weekly 
was then taken as the RP2D in combination with weekly 
trastuzumab.
In this study, 22.0% of patients treated at 70 mg/
m2 achieved ORR by investigator review. Furthermore, 
stable disease was reported in 48.8% of patients treated 
at 70 mg/m2. Thus, our results confirm that HSP90 
inhibition in combination with trastuzumab is a promising 
strategy in advanced or metastatic HER2-positive breast 
cancer patients progressing on trastuzumab. The results 
are comparable to that seen with tanespimycin plus 
trastuzumab combination, where ORR was 22% and 
disease stabilization rate was 37% [30]. In the first-in-
human monotherapy study of AUY922, which included 
metastatic breast cancer [29], none of the patients had 
objective responses; this may be due to the following 
2 reasons: the patients in the first-in-human study were 
not molecularly prioritized before study entry; and the 
responses seen in this study may be due to the combination 
of trastuzumab with AUY922. Despite the promising ORR 
and disease stabilization rate, the median PFS and OS 
were only 3.94 months and 12.65 months, respectively.
The trough trastuzumab concentrations following 
administration of trastuzumab were higher than 30 μg/mL, 
which is consistent with the observations reported in the 
literature [32]. The pharmacokinetic profile of AUY922 
in combination with trastuzumab seen in this study is 
consistent with that observed in the AUY922 first-in-
human monotherapy study [29].
The safety profile of AUY922 plus trastuzumab 
was similar to the safety profile of AUY922 monotherapy 
in the first-in-human study with the most common AEs 
being gastrointestinal and ocular [29]. Of note, a majority 
of patients (82.3%) had grade 1 or 2 ocular AEs; grade 
3 and grade 4 ocular AEs were reported in 3 (6.7%) and 
1 patients (2.2%), respectively. Overall, only 2 patients 
discontinued the treatment due to ocular events; other 
ocular events (mostly ≥ grade 2) were managed by study 
treatment dosage adjustment/temporary interruption 
and/or use of concomitant medication. However, ocular 
events seen in this study were not unexpected, as it has 
been reported in the first-in-human AUY922 monotherapy 
study where ocular events related to AUY922 occurred in 
43% of patients (grade 1 or 2 in 41 of 101 patients [41%] 
and grade 3 in 2 of 101 patients [2%]). Of note, ocular 
events were not reported in HER2-positive breast cancer 
patients treated with tanespimycin [30]. The difference 
in ocular toxicity in AUY922 and tanespimycin may be 
due to high retina/plasma concentration ratio and slow 
elimination profile of AUY922 [33].
The anti-HER2 paradigms for metastatic breast 
cancer have changed since the initiation of this study; 
pertuzumab is approved in combination with trastuzumab 
and docetaxel as first-line treatment for patients with 
HER2-positive metastatic breast cancer who have not 
received prior anti-HER2 therapy or chemotherapy for 
metastatic disease, whereas TDM-1 is approved for 
patients with HER2-positive metastatic breast cancer 
previously treated with trastuzumab.
In conclusion, the combination of AUY922 at 70 
mg/m2 and trastuzumab standard therapy is well tolerated 
and active in patients with HER2-positive metastatic 
breast cancer who progressed on trastuzumab-based 
therapy; however, this needs to be explored further in a 
larger population. Although there are no clinical studies 
ongoing with AUY922 in metastatic breast cancer, this 
study has provided further rationale for combining HSP90 
inhibitor with trastuzumab in pretreated HER2-positive 
breast cancer patients.
PATIENTS AND METHODS
Patients
Female patients, who were aged ≥ 18 years 
with confirmed HER2-positive, nonoperable, locally 
advanced or metastatic breast cancer who progressed 
on prior anti–HER2-based regimens including at least 
1 regimen containing trastuzumab, were eligible. HER2 
overexpression was based on either immunohistochemistry 
at the 3+ level or immunohistochemistry 2+ level 
confirmed by fluorescence in situ hybridization.
Patients who developed metastases while receiving 
adjuvant trastuzumab were eligible, and their adjuvant 
therapy was considered as 1 prior regimen.
Patients who received lapatinib as a last line of 
treatment were eligible. Other key inclusion criteria were 
≥ 1 measurable lesion as defined by Response Evaluation 
Criteria In Solid Tumors version 1.0 (RECIST), 
documented progressive disease following the last line 
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of therapy, and Eastern Cooperative Oncology Group 
performance status of ≤ 1.
Patients were excluded if they had the following: 
known symptomatic central nervous system metastases 
requiring treatment (for symptom control and/or 
growing); impaired cardiac function; received prior 
treatment with any HSP90 or histone deacetylase 
inhibitor; systemic anticancer treatment prior to AUY922 
dosing (radiotherapy, chemotherapy, hormonotherapy, 
investigational drugs, and monoclonal antibodies other 
than trastuzumab within 4 weeks; palliative radiotherapy 
within 2 weeks; and nitrosoureas and mitomycin within 6 
weeks); unresolved diarrhea > Common Toxicity Criteria 
for Adverse Events version 4.0 (CTCAE) grade 1; not 
recovered from the reversible side effects of previous 
systemic anticancer therapy (except for alopecia) < 
CTCAE grade 2 prior to the first dose; therapeutic 
doses of sodium warfarin; acute or chronic liver or renal 
disease; other concurrent severe and/or uncontrolled 
medical conditions that could cause unacceptable safety 
risks; known hypersensitivity to any study medication; 
and history of another primary malignancy that was 
currently clinically significant or currently required active 
intervention.
The study protocol and all amendments were 
reviewed by the Independent Ethics Committee or 
Institutional Review Board for each center. The study was 
conducted according to Good Clinical Practice guidelines 
and ethical principles of the Declaration of Helsinki. All 
patients provided written informed consent.
Study design and treatment
This open-label, nonrandomized, multicenter study 
(NCT01271920) was composed of a dose-escalation 
part with AUY922 administered at escalating doses in 
combination with trastuzumab at the standard dose (phase 
1B), followed by a phase 2 part using the same regimen 
with AUY922 and trastuzumab at RP2D. AUY922 was 
administered as once weekly 1-hour intravenous infusion 
with trastuzumab at the licensed weekly dose of 2 mg/kg 
over 30 minutes (or 4 mg/kg over 90 minutes if a loading 
dose was necessary at cycle 1 day 1) on days 1, 8, 15, 
and 22 of each 28-day treatment cycle. Patients received 
treatment until disease progression, unacceptable toxicity, 
or investigator’s/patient’s decision to discontinue the 
treatment.
A 2-parameter Bayesian logistic regression model 
employing the escalation with overdose control (EWOC) 
principle [34, 35] was used during the dose-escalation 
phase to guide dose-level selection and determination 
of the MTD/RP2D. The starting dose of AUY922 was 
55 mg/m2 in phase 1B and was determined based on 
EWOC criteria and data from first-in-human AUY922 
monotherapy study [29]. The primary objective for phase 
1B was to determine the MTD and/or RP2D of AUY922 
plus trastuzumab, whereas the primary objective of the 
phase 2 component was to evaluate preliminary antitumor 
activity (ORR) of AUY922 plus trastuzumab at the 
MTD/RP2D. Secondary objectives include evaluation 
of pharmacokinetics, safety, tolerability, and preliminary 
efficacy (PFS, OS) for AUY922 in combination with 
trastuzumab standard therapy.
Patient assessments
Safety assessments consisted of monitoring by 
investigators and recording all AEs and SAEs (up to 
28 days following the last dose of AUY922), and the 
regular monitoring of laboratory evaluations, physical 
examination, vital signs, weight, performance status 
evaluation, electrocardiograms and repeat cardiac 
assessments, cardiac enzymes, echocardiogram and or 
multigated acquisition scan (if clinically indicated). 
Ophthalmologic examinations were also to be performed 
at the end of cycle 2 and end of treatment or more often 
if any visual symptom was reported. Toxicity was 
assessed using the National Cancer Institute CTCAE, 
version 4.0.
All patients were to be followed for AEs and 
SAEs for 28 days following the last dose of AUY922. 
Pharmacokinetic parameters were determined by 
noncompartmental method(s) using WinNonlin® Pro 
(version 5.2). Tumor response was assessed by the 
investigators according to RECIST version 1.0 [36]. 
Tumor assessments using CT or magnetic resonance 
imaging were to be performed every 8 weeks for first 24 
weeks and every 12 weeks thereafter until progression 
or until a new anticancer therapy was initiated. The best 
overall response of SD was defined as having at least 
one SD assessment (or better) > 6 weeks after start of 
treatment (and not qualifying for CR or PR).
Statistical methods
The EWOC principle [34, 35] mandated that 
any dose of AUY922 in combination with the standard 
trastuzumab therapy that had more than a 25% chance of 
being in the excessive toxicity category (true DLT rate in 
the interval [33%, 100%]) was not considered for the next 
dose cohort. Prior distributions for the Bayesian logistic 
regression model parameters were based on data from the 
AUY922 first-in-human study [29].
For phase 1B, 3 to 6 patients evaluable for the 
Bayesian logistic regression model were to be treated per 
cohort, until the MTD/RP2D was reached, and ≥ 6 patients 
evaluable for the dose-determining set were to be treated 
at the MTD/RP2D. With the use of historical data from 
the AUY922 first-in-human study [29] in an informative 
prior distribution, it was estimated that approximately 12 
patients would need to be enrolled on study for the model 
to have reasonable operating characteristics.
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The phase 2 part used a Bayesian design to estimate 
the ORR observed with this regimen with AUY922 at the 
identified MTD and/or RP2D. For phase 2 part, given an 
observed ORR equal to 30%, approximately 40 patients 
(including those already treated at the RP2D during the 
phase 1B part) were planned for the model to have less 
than 10% posterior risk of the true response rate being less 
than 20%.
PFS and OS were estimated by Kaplan-Meier 
method.
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